Treatment of Raynaud’s phenomenon with botulinum toxin type A

详细信息    查看全文

• 作者：Xiaolong Zhang ; Yong Hu ; Zhiyu Nie ; Ye Song ; Yougui Pan ; Ying Liu…
• 关键词：Botulinum toxin ; Raynaud’s phenomenon ; Ultrasonography ; Therapy
• 刊名：Neurological Sciences
• 出版年：2015
• 出版时间：July 2015
• 年：2015
• 卷：36
• 期：7
• 页码：1225-1231
• 全文大小：740 KB
• 参考文献：1.Goundry B, Bell L, Langtree M, Moorthy A (2012) Diagnosis and management of Raynaud’s phenomenon. BMJ 344:e289PubMed View Article
  2.Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, Mendoza-Pinto C, Pardo-Santos R, Levy R, Maldonado CG, Chavez GP, Cervera R (2008) Treatment of Raynaud’s phenomenon. Autoimmun Rev 8(1):62-8PubMed View Article
  3.Carpentier PH, Satger B, Poensin D, Maricq HR (2006) Incidence and natural history of Raynaud phenomenon: a long-term follow-up (14?years) of a random sample from the general population. J Vasc Surg 44(5):1023-028PubMed View Article
  4.Devulder J, van Suijlekom H, van Dongen R, Diwan S, Mekhail N, van Kleef M, Huygen F (2011) Ischemic pain in the extremities and Raynaud’s phenomenon. Pain Pract 11(5):483-91PubMed View Article
  5.Levien TL (2010) Advances in the treatment of Raynaud’s phenomenon. Vasc Health Risk Manage 6:167-77View Article
  6.Vaya A, Alis R, Romagnoli M, Todoli J, Calvo J, Ricart JM (2013) Hemorheological profile in primary and secondary Raynaud’s phenomenon. influence of microangiopathy. Clin Hemorheol Microcirc 56(3):259-64
  7.Vaya A, Sanchez F, Todoli J, Calvo J, Alis R, Collado S, Ricart JM (2014) Homocysteine levels in patients with primary and secondary Raynaud’s phenomenon. Its association with microangiopathy severity. Clin Hemorheol Microcirc 56(2):153-59PubMed
  8.Mannava S, Plate JF, Stone AV, Smith TL, Smith BP, Koman LA, Tuohy CJ (2011) Recent advances for the management of Raynaud phenomenon using botulinum neurotoxin A. J Hand Surg 36(10):1708-710View Article
  9.Trindade De Almeida AR, Secco LC, Carruthers A (2011) Handling botulinum toxins: an updated literature review. Dermatol Surg 37(11):1553-565PubMed View Article
  10.Jin L, Kollewe K, Krampfl K, Dengler R, Mohammadi B (2009) Treatment of phantom limb pain with botulinum toxin type A. Pain Med 10(2):300-03PubMed View Article
  11.Jensen TS, Madsen CS, Finnerup NB (2009) Pharmacology and treatment of neuropathic pains. Curr Opin Neurol 22(5):467-74PubMed View Article
  12.Bertram K, Sirisena D, Cowey M, Hill A, Williams DR (2013) Safety and efficacy of botulinum toxin in primary orthostatic tremor. J Clin Neurosci 20(11):1503-505PubMed View Article
  13.Sycha T, Graninger M, Auff E, Schnider P (2004) Botulinum toxin in the treatment of Raynaud’s phenomenon: a pilot study. Eur J Clin Invest 34(4):312-13PubMed View Article
  14.Iorio ML, Masden DL, Higgins JP (2012) Botulinum toxin A treatment of Raynaud’s phenomenon: a review. Semin Arthritis Rheum 41(4):599-03PubMed View Article
  15.Flatt AE (1980) Digital artery sympathectomy. J Hand Surg 5(6):550-56View Article
  16.Balogh B, Mayer W, Vesely M, Mayer S, Partsch H, Piza-Katzer H (2002) Adventitial stripping of the radial and ulnar arteries in Raynaud’s disease. J Hand Surg 27(6):1073-080View Article
  17.Ward WA, Van Moore A (1995) Management of finger ulcers in scleroderma. J Hand Surg 20(5):868-72View Article
  18.Yee AM, Hotchkiss RN, Paget SA (1998) Adventitial stripping: a digit saving procedure in refractory Raynaud’s phenomenon. J Rheumatol 25(2):269-76PubMed
  19.Wheeler A, Smith HS (2013) Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology 306:124-46PubMed View Article
  20.Van Beek AL, Lim PK, Gear AJ, Pritzker MR (2007) Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg 119(1):217-26PubMed View Article
  21.Fregene A, Ditmars D, Siddiqui A (2009) Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud’s phenomenon. J Hand Surg 34(3):446-52View Article
  22.Neumeister MW (2010) Botulinum toxin type A in the treatment of Raynaud’s phenomenon. J Hand Surg 35(12):2085-092View Article
  23.Neumeister MW, Chambers CB, Herron MS, Webb K, Wietfeldt J, Gillespie JN, Bueno RA Jr, Cooney CM (2009) Botox therapy for ischemic digits. Plast Reconstr Surg 124(1):191-01PubMed View Article
  24.Setler PE (2002) Therapeutic use of botulinum toxins: background and history. Clin J Pain 18(6 Suppl):S119–S124PubMed View Article
  25.Flavahan NA, Vanhoutte PM (1986) Effect of cooling on alpha-1 and alpha-2 adrenergic responses in canine saphenous and femoral veins. J Pharmacol Exp Ther 238(1):139-47PubMed
  26.Jinsi-Parimoo A, Deth RC (1997) Reconstitution of alpha2D-adrenergic receptor coupling to phospholipase D in a PC12 cell lysate. J Biol Chem 272(23):14556-4561PubMed View Article
  
• 作者单位：Xiaolong Zhang (1)
  Yong Hu (1)
  Zhiyu Nie (1)
  Ye Song (2)
  Yougui Pan (1)
  Ying Liu (1)
  Lingjing Jin (1)
  
  1. Department of Neurology, Shanghai Tongji Hospital, Tongji University School of Medicine, Xin-Cun Road 389, Shanghai, 200065, China
  2. Department of ultrasound, Shanghai Tongji Hospital, Tongji University School of Medicine, Xin-Cun Road 389, Shanghai, 200065, China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Neurology
  Neuroradiology
  Neurosurgery
  Psychiatry
  
• 出版者：Springer Milan
• ISSN：1590-3478

文摘

Raynaud’s phenomenon (RP), an episodic vasospasm of the peripheral arteries, is quite common in general population. The current therapies of RP are limited by efficacy, side effects, and polypharmacy concerns. Botulinum toxin type A (BTX-A) local injections have been reported for the treatment of RP, but the injection sites, concentration and dose of BTX-A were different from each other in previous trials. In addition, so far, there have been no reports concerning local injection of BTX-A in Asian RP patients. Ten patients with RP in China were included in this retrospective study. All the patients had intractable pain and were non-responsive to conservative and/or medical therapy. A patterned BTX-A injection was performed in RP patients, guided by ultrasonography. BTX-A was injected as 20?u/ml devoid of preservatives. Outcomes were measured by ultrasonography, surface temperature, visual analog scale (VAS) for clinical symptoms (pain, numbness, stiffness and swelling), and changes in ulcers or gangrene. Overall, a great improvement in artery flow velocity (P?<?0.01), surface temperature (P?<?0.01), ulcer and VAS for clinical symptoms, was observed after BTX-A local injection. Complications were very rarely found, and no patients complained of hand weakness and bruise. BTX-A patterned injection guided by ultrasonography might be a useful therapeutic tool in the management of intractable RP.